Lung Cancer (Suspected or Confirmed) clinical trials

Study of A2B395 therapy for solid tumors with EGFR and HLA loss

This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.

EXS74539 Study for Advanced Solid Tumors

This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.

Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer

This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Trial: Adjusting Atezolizumab Dose Based on Drug Levels in Blood

This study tests whether adjusting the dose of the immunotherapy drug atezolizumab (Tecentriq) based on its levels in your blood works well. You may be able to join if you have advanced cancer and your doctor already plans to give you this drug (alone or with other approved treatments).

Osimertinib for lung cancer with an EGFR exon 20 change

This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.

Ubamatamab with or without REGN7075 for advanced lung cancer

This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.

Study for people with stage IV lung cancer

This study focuses on improving outcomes for people with stage IV non-small cell lung cancer by gathering health, treatment, and lifestyle information. It may help researchers understand what supports survival and care planning, especially for people who are current smokers or recent quitters.

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Guided surgery for small deep lung cancers

This trial tests a new surgical technique to remove small, early-stage lung cancers that are located deep within the lung tissue. The goal is to remove only the affected area while preserving as much healthy lung as possible.

Combination therapy for STK11-mutant lung cancer

This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.

Lung nodule study using blood and tissue metabolism

This trial follows people with lung nodules over time, using blood and tissue samples to look for metabolic changes that may help understand lung cancer better. If you have a lung nodule found on a CT scan and can safely do lung function tests, this study may be a fit.

Reduced-dose chemotherapy for advanced lung cancer

This trial studies a lower (reduced) dose of chemotherapy in people with advanced lung cancer who may not tolerate standard treatment. It aims to see if the treatment still works while being safer for “compromised” patients.

Study uses data to tailor lung cancer care with immunotherapy

This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.

Blood test DNA levels after lung surgery

This study looks at how different lung surgical techniques affect levels of tumor DNA in the blood before and after surgery for early-stage lung cancer. It may help doctors choose surgical approaches and use a blood test to monitor cancer after surgery.

AI-guided radiation plan for lung cancer tumors

This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.

Study of SX-682 with atezolizumab for advanced lung cancer

This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.

PET/CT for distinguishing non-small cell lung cancer

This study uses a special PET/CT scan to better tell if a lung nodule is non-small cell lung cancer. If you have a solid nodule in your lung that's at least 8 mm and might be cancer, this scan could help get a clearer diagnosis.

Implantable radiation sheet for early-stage lung cancer

This Phase 2 study tests whether a permanently implanted, low-dose radiation “sheet” can be used to treat certain early-stage lung cancers. It may help shrink or control tumors while delivering radiation directly at the cancer site.

New radiation technique for early-stage lung cancer

This trial compares a newer, more targeted type of radiation (hotspot SABR) with the standard SABR approach for people with early-stage non-small cell lung cancer. The goal is to see if the newer method works just as well or better while possibly reducing side effects.

Real-world study of Tislelizumab for lung cancer

This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.

Liquid biopsy to improve lung cancer screening

This study tests whether a simple blood test (liquid biopsy) can help find lung cancer earlier in people at high risk. It also includes people already diagnosed with lung cancer to refine the test.

Chemo, immunotherapy and targeted radiation before surgery for advanced lung cancer

This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.

Personalized vaccine for first-line advanced lung cancer

This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.